Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles
Open Access
- 8 November 2025
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (6) , 1611-1622
Abstract
Background: Rituximab is considered a therapeutic option in children with refractory nephrotic syndrome (RNS). However, the efficacy and safety of rituximab treatment remain unclear. Objective: This study systematically evaluated the clinical effectiveness and related adverse event profiles of rituximab compared with other immunosuppressants in children with RNS. Method: Two independent investigators conducted the methodological rigor evaluation in a double-blind manner. Statistical analyses were performed using RevMan 5.4. Results: Relative to other conventional second-line agents, rituximab therapy presented a significantly increased relapse-free survival rate [vs. tacrolimus: OR = 3.42, 95% CI = 1.96–5.94, P < 0.01]. Fewer adverse drug reactions occurred in patients with rituximab than with other immunosuppressants [vs. cyclophosphamide: OR = 0.18, 95% CI = 0.04–0.89, P = 0.03; vs. tacrolimus: OR = 0.26, 95% CI = 0.07–0.92, P = 0.04]. The application of rituximab increased the steroid-discontinued rate and decreased the corticosteroid dose in the treatment [vs. cyclophosphamide: OR = 5.46, 95% CI = 2.00–14.92, P = 0.0009; vs. tacrolimus: OR = 3.42, 95% CI = 1.67–7.01, P = 0.0008]. Conclusion: Our study demonstrates rituximab’s superior efficacy and safety profile compared to conventional second-line immunosuppressants in pediatric RNS, particularly regarding steroid minimization. Systematic review registration number: CRD420251082051. GraphicalKeywords
This publication has 37 references indexed in Scilit:
- Corticosteroid therapy for nephrotic syndrome in childrenCochrane Database of Systematic Reviews, 2024
- Anti-nephrin antibodies in steroid-sensitive nephrotic syndrome in Japanese childrenPediatric Nephrology, 2023
- Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus NephritisJAMA Network Open, 2022
- Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trialPediatric Nephrology, 2022
- Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndromePediatric Nephrology, 2022
- Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young AdultsJAMA Pediatrics, 2021
- Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndromePediatric Nephrology, 2020
- The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysisInternational Urology and Nephrology, 2020
- Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trialPediatric Nephrology, 2020
- Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic SyndromeJAMA Pediatrics, 2018